Get started
AJANTA PHARMA LTDAJANTA PHARMA LTDAJANTA PHARMA LTD

AJANTA PHARMA LTD

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

AJANTPHARM chart


Full chart

AJANTPHARM upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪352.04 B‬ INR
Dividend yield (indicated)
1.92%
Price to earnings Ratio (TTM)
40.60
Basic EPS (TTM)
69.65 INR
Net income (FY)
‪8.16 B‬ INR
Revenue (FY)
‪41.82 B‬ INR
Shares float
‪41.47 M‬
Beta (1Y)
0.07

Employees


Employees (FY)
‪10.37 K‬
Change (1Y)
+98 +0.95%
Revenue / Employee (1Y)
‪4.03 M‬ INR
Net income / Employee (1Y)
‪787.20 K‬ INR

About AJANTA PHARMA LTD


Sector
Health Technology
Headquarters
Mumbai
Founded
1973
Website
ajantapharma.com
ISIN
INE031B01049
FIGI
BBG000CQGCV0
Ajanta Pharma Ltd. is a holding company, which engages in the development, manufacture, and marketing of pharmaceutical products. The firm offers branded generics and generics that serve a range of therapeutic segments such as antibiotic, anti-malarial, anti-diabetic, cardiology, gynecology, orthopedics, pediatric, respiratory, and general health. It operates through the following geographical segments: India, Africa, Asia, and USA. The company was founded by Purushottam Bhagwand Agrawal in 1973 and is headquartered in Mumbai, India.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

AJANTPHARM news



Ideas


AJANTA PHARMA LTDBuy Ajanta above: 3351 only. All important points are marked. 𝐃𝐢𝐬𝐜𝐥𝐚𝐢𝐦𝐞𝐫: 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐢𝐧 𝐬𝐞𝐜𝐮𝐫𝐢𝐭𝐢𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐚𝐫𝐞 𝐬𝐮𝐛𝐣𝐞𝐜𝐭 𝐭𝐨 𝐦𝐚𝐫𝐤𝐞𝐭 𝐫𝐢𝐬𝐤𝐬, 𝐫𝐞𝐚𝐝 𝐚𝐥𝐥 𝐭𝐡𝐞 𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐝𝐨𝐜𝐮𝐦𝐞𝐧𝐭𝐬 𝐜𝐚𝐫𝐞𝐟𝐮𝐥𝐥𝐲 𝐛𝐞𝐟𝐨𝐫𝐞 𝐢𝐧𝐯𝐞𝐬𝐭𝐢𝐧𝐠. 𝐒𝐭𝐨𝐜𝐤𝐬 𝐬𝐮𝐠𝐠𝐞𝐬𝐭𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐠𝐫𝐨𝐮𝐩 𝐚𝐫𝐞 𝐟𝐨𝐫 𝐞𝐝𝐮𝐜𝐚𝐭𝐢𝐨𝐧 𝐩𝐮𝐫𝐩𝐨𝐬𝐞. 𝐖𝐞 𝐝𝐨𝐧𝐭 𝐦𝐚𝐤𝐞 𝐚𝐧𝐲 𝐩𝐫𝐨𝐟𝐢𝐭𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐢𝐬 𝐫𝐞𝐜𝐨𝐦𝐦𝐞𝐧𝐝𝐚𝐭𝐢
NSE:AJANTPHARMLong
by sreekumars

See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of AJANTPHARM is 2,793.70 INR — it has decreased by −1.08% in the past 24 hours. Watch AJANTA PHARMA LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NSE exchange AJANTA PHARMA LTD stocks are traded under the ticker AJANTPHARM.
AJANTPHARM stock has fallen by −6.39% compared to the previous week, the month change is a −2.15% fall, over the last year AJANTA PHARMA LTD has showed a 47.28% increase.
We've gathered analysts' opinions on AJANTA PHARMA LTD future price: according to them, AJANTPHARM price has a max estimate of 3,665.00 INR and a min estimate of 2,590.00 INR. Watch AJANTPHARM chart and read a more detailed AJANTA PHARMA LTD stock forecast: see what analysts think of AJANTA PHARMA LTD and suggest that you do with its stocks.
AJANTPHARM reached its all-time high on Sep 12, 2024 with the price of 3,485.00 INR, and its all-time low was 1.80 INR and was reached on Mar 28, 2003. View more price dynamics on AJANTPHARM chart.
See other stocks reaching their highest and lowest prices.
AJANTPHARM stock is 2.66% volatile and has beta coefficient of 0.07. Track AJANTA PHARMA LTD stock price on the chart and check out the list of the most volatile stocks — is AJANTA PHARMA LTD there?
Today AJANTA PHARMA LTD has the market capitalization of ‪352.04 B‬, it has decreased by −5.39% over the last week.
Yes, you can track AJANTA PHARMA LTD financials in yearly and quarterly reports right on TradingView.
AJANTA PHARMA LTD is going to release the next earnings report on Jan 29, 2025. Keep track of upcoming events with our Earnings Calendar.
AJANTPHARM earnings for the last quarter are 17.26 INR per share, whereas the estimation was 18.00 INR resulting in a −4.11% surprise. The estimated earnings for the next quarter are 18.10 INR per share. See more details about AJANTA PHARMA LTD earnings.
AJANTA PHARMA LTD revenue for the last quarter amounts to ‪12.06 B‬ INR, despite the estimated figure of ‪11.45 B‬ INR. In the next quarter, revenue is expected to reach ‪11.52 B‬ INR.
AJANTPHARM net income for the last quarter is ‪2.16 B‬ INR, while the quarter before that showed ‪2.46 B‬ INR of net income which accounts for −11.92% change. Track more AJANTA PHARMA LTD financial stats to get the full picture.
As of Dec 11, 2024, the company has ‪10.37 K‬ employees. See our rating of the largest employees — is AJANTA PHARMA LTD on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AJANTA PHARMA LTD EBITDA is ‪12.67 B‬ INR, and current EBITDA margin is 28.18%. See more stats in AJANTA PHARMA LTD financial statements.
Like other stocks, AJANTPHARM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AJANTA PHARMA LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AJANTA PHARMA LTD technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AJANTA PHARMA LTD stock shows the buy signal. See more of AJANTA PHARMA LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.